Presentation is loading. Please wait.

Presentation is loading. Please wait.

Partnering for Growth Thomas Jefferson University, June 7th, 2013 Chris Yochim, Director, External Relations Strategic Partnering and Business Development.

Similar presentations


Presentation on theme: "Partnering for Growth Thomas Jefferson University, June 7th, 2013 Chris Yochim, Director, External Relations Strategic Partnering and Business Development."— Presentation transcript:

1 Partnering for Growth Thomas Jefferson University, June 7th, 2013 Chris Yochim, Director, External Relations Strategic Partnering and Business Development

2 Partnering for Growth Agenda Our strategic priorities and platforms for growth Partnering strategy and capabilities Academic Collaborations to drive scientific leadership 2

3 Driving strategic priorities 3 Achieve scientific leadership Focus on 3 distinct core disease areas Prioritise and accelerate our pipeline Strengthen our capabilities in translational science and personalised medicine Transform our innovation and culture model

4 We will focus on distinctive science in our core therapy areas 4 Neuroscience Infection & Vaccines Cardio- Metabolism Respiratory/ inflammation Core TAs Oncology Opportunity-Driven Protein engineering Biologics Small Molecules Immuno-therapies

5 Build biologics/specialty care potential to drive sustainable longer term growth 5 On track for sustainable delivery of 1 BLA/year from 2016 Convert strong biologics pipeline into future launches Create a balanced primary and specialty care product portfolio Development Pipeline Today ~50% Biologics ~50% Small Molecules BLA = Biologics License Application Development (Phase I-III) pipeline today has grown to ~50% biologics Return to growth 2

6 Saudi Arabia ~$170 Million China ~$1.5 Billion Russia ~$300 Million Brazil ~$500 Million Mexico ~$240 Million Turkey ~$250 Million S. Korea ~$240 Million AZ Emerging Markets – A platform for success 6 Source: Internal 2012 Ex Factory Sales / IMS 6 th fastest growing MNC pharma player across Emerging Markets ~$6bn sales in Emerging Markets

7 Partnering for Growth Agenda Our strategic priorities and platforms for growth Partnering strategy and capabilities Academic Collaborations to drive scientific leadership 7

8 Approximately 40% of our pipeline is sourced through external partnerships AstraZeneca partnering strategy is focused on supplementing and complementing our core therapy areas and scientific capabilities Pursue in-licensing and bolt-on acquisitions that strengthen the core TA portfolios Seek 1-2 additional global peer-to-peer partnerships beyond BMS and Amgen alliances Increased focus on early stage research deals and academic alliances in 2013 Working in collaboration is an ongoing part of our new strategy 8

9 9 Building direct early access to our R&D ScoutingDiligenceTransactionAlliance Mgmt Global Medicines Development Internal and external opportunities Market Innovative Medicines Units Small Molecules Innovative Medicines Units Biologics Late-stage Development Discovery and Early Development R&D Enabling functions Cardiovascular/ Gastrointestinal OncologyRespiratory and Inflammation CNS and Pain InfectionNew Opportunities Science and Technology Personalised Healthcare and Biomarkers Emerging Markets and Asia R&D Cross functional transaction team

10 Truly global commercial operations footprint with both primary and specialty care focus A large and growing presence in emerging markets including China, Brazil, Russia Sales, marketing and medical excellence to tailor brands and drive performance in 100 countries Innovative sales and marketing channels to better serve the needs of today’s customers Life-cycle management expertise to help extend the value of the products we market As a Commercial partner we bring.... 10

11 As a Development partner we bring... 90% of pipeline addresses payer evidence to support reimbursement 87% of projects apply new methods of clinical design and interpretation A global R&D footprint with local insights and capabilities World-class regulatory, manufacturing and protein engineering capabilities 11 75% of our portfolio applies a personalised healthcare approach

12 Partnering for Growth Agenda Our strategic priorities and platforms for growth Partnering strategy and capabilities Academic Collaborations to drive scientific leadership 12

13 Academic Alliance: History of strategic collaboration Key Strategic Alliances (Since Jan 2011) Collaborative Research (201) Consortiums & Foundations (41) –Dundee –Biomarker/Safety –Regional Economic Development –Medicines for Malaria –TB Consortium MTA’s 300+ 13

14 Creative alliances to drive early scientific discovery projects A5 alliance, to study a major risk factor for Alzheimer's disease, the apolipoprotein E4 genotype (ApoE) –Alzheimer's Disease Research Institute at Weill Cornell, Washington University in St Louis, The Feinstein Institute for Medical Research and the University of British Columbia. 7 Way-Consortium: Critical Path to TB Drug Regimens –AstraZeneca, Bayer, Sanofi and Tibotec have signed on with TB Alliance and the World Health Organization to share information about the TB compounds in their pipelines to quickly identify and collaborate to develop the most promising TB drug regimens AZ & GSK forge alliance with Univ. Manchester Collaborative Centre for Inflammation –Unique Pre-Competitive collaboration to establish a world-leading translational centre for inflammatory diseases. Scientists will be recruited for new positions to direct the research in line with strategic priorities set jointly by GSK, AstraZeneca and The University of Manchester, with the ultimate goal of translating findings into new and improved treatments. Broad Institute –The Broad Institute's 100,000 compound library will be tapped for weapons against drug resistant strains of bacteria. targeted towards the discovery of new antibiotics and other treatments for infectious diseases. 14

15 Fostering Alliances for Clinical Development Fostering helps us to broaden our drug development activity by working with experienced clinical development institutions which can take the lead on early-stage development of AstraZeneca compounds. When the compounds reach the proof-of-concept stage, we can opt in and continue development with a milestone payment, or we can opt out and receive a royalty later on when the compound is approved and commercialized –Singapore National University and the National Cancer Centre development of AstraZeneca compounds for hepato-cellular carcinoma which have already undergone clinical testing in western locations. Applying their experience to conduct clinical trials in wider patient populations, broadening our drug development capabilities in Asia. –Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm. AstraZeneca’s compound, AZD- 3965 – a first-of-its-kind experimental drug to potentially treat a range of cancers- into clinical development. Working with CRT will enable a compound with a very exciting mechanism to be evaluated in patients using Cancer Research UK’s extensive clinical network. 15

16 Partnering areas of interest Cardiovascular & Gastrointestinal Our research focuses on small molecule and biologics for diabetes and diabetic complications, obesity, atherosclerosis, haemostasis, gastrointestinal, abdominal aortic aneurysm, bleeding disorders as well as re-profiling compounds, innovative drug-delivery systems and regenerative medicine. Oncology Our small and large molecule research focuses on cancer of the breast, prostate, gastrointestinal tract, lung, as well as haematological malignancies, “niche” cancers, novel technologies and biomarkers. Respiratory & Inflammation We are particularly interested in asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, systemic lupus erythematosus and novel inhalation approaches. 16

17 Partnering areas of interest Infection Our partnership interests also include: viral infections such as respiratory viruses (e.g flu, RSV), HCV, HBV and herpes family viruses, as well as systemic fungal infections, and diagnostics. Novel vaccines to address bacterial and viral infections with limited current treatment options are also of interest. Neuroscience We are interested in small and large molecule research to discover and develop new treatments in neurology, psychiatry and pain. Personalised Healthcare & Biomarkers We are looking for additional biomarker capabilities that can deliver clinically meaningful segmentation of therapeutic response, including methodology for patient selection, disease identification, and pharmacological assessment. Science & Technology Key areas of interest include predictive safety and predictive efficacy platforms, target validation tools and technologies, novel HTS/lead generation approaches, novel chemical libraries with evidence of biological relevance, stem cell biology and, novel technologies for antibodies and vaccines. 17

18 18 Personalised Healthcare – an open approach to collaboration Partnership and collaboration at the core of PHC strategy –No single partner can address all of our PHC needs –Series of partnerships will help us to achieve our aims Strategic alliances with key academic centres and independent diagnostic developers Early engagement with partners enables us to share needs and match up partner products

19 19 Differentiated value proposition vs. future standard of care Invest to win / priority areas – DTPP / CDTP Market access / payer / provider focus Personalised healthcare strategy including diagnostic / biomarkers Diligence Process: Five Dimensions for success Strong link between target and disease Differentiating efficacy Available and predictive biomarkers Adequate bioavailability and tissue exposure Human PK / PD prediction, PD biomarkers Drug-drug interaction Clear assessment of safety risks Clear understanding of risk-benefit Availability of predictive biomarkers Scientific evidence in lead indication Risk / benefit stratification of patient population PHC strategy including diagnostic / biomarkers Right target Right tissue/ Right exposure Right safety Right patients Right commercial

20 Desire to create partnerships that achieve mutual goals Rapid evaluation and insightful feedback to partners Alliance management continuity throughout the deal life cycle Focused commitment to early and late-stage partnering Expertise in biologics and small molecule discovery, development and manufacturing Exceptional commercial and R&D presence in emerging markets and Asia Innovative commercial channels, underpinned by global reach Exclusive focus on innovative pharmaceutical medicines Access to early payer and regulatory involvement to secure reimbursement and market access 20 Why Partner with AstraZeneca? 20

21 21 For more information about partnering with AstraZeneca, visit astrazeneca.com/partnering Chris.yochim@astrazeneca.com


Download ppt "Partnering for Growth Thomas Jefferson University, June 7th, 2013 Chris Yochim, Director, External Relations Strategic Partnering and Business Development."

Similar presentations


Ads by Google